Since APOE*ε2 carriers have higher levels of plasma APOE [48–51] and HDL [92, 93], whole plasma or plasma APOE-containing lipoprotein particles from APOE*ε2 carriers may hold promise as a therapeutic strategy for AD. Here, APOE is linked to Alzheimer disease.